Safety data for secukinumab in patients with psoriasis and viral hepatitis are lacking. The
aim of this study is to investigate the risk of reactivation of hepatitis B virus (HBV)/hepatitis C …

Abstract Background and Objective Biologics for psoriasis, especially anti-tumor necrosis
factor-α therapies, may reactivate hepatitis B virus (HBV) or hepatitis C virus (HCV) …

Background: There is limited long-term, real-world evidence on the efficacy and safety in
patients with plaque psoriasis treated with secukinumab. We present results at 136 weeks in …

Background: The efficacy and safety of secukinumab in patients with plaque psoriasis (PsO)
have been demonstrated in randomized clinical trials (RCTs). However, data regarding its …

Introduction: Secukinumab is a human monoclonal antibody that selectively targets and
neutralizes interleukin (IL)-17A, a cytokine that is normally involved in mucocutaneous …

Background Long-term real-life data on secukinumab use in psoriasis are limited. Objectives
Determine the long-term effectiveness of secukinumab in moderate-to-severe psoriasis in …

Abstract Secukinumab (anti‐IL17A) is effective as treatment for moderate to severe plaque
psoriasis, but real‐life data on effectiveness and safety lack. We aimed to present real‐life …

Background Some biologics for psoriasis, especially anti-tumor necrosis factor (TNF)-α
therapies, may re-activate latent tuberculosis (TBC) infection with consequent morbidity and …

To evaluate drug survival of secukinumab in a daily practice setting, we retrospectively
evaluated all psoriatic patients starting secukinumab during January 2016-February 2017 at …

Background: Secukinumab is a fully human monoclonal antibody that neutralizes interleukin-
17A (IL-17A), a key cytokine involved in the development of psoriasis. Here, we …